Anacor gets a key pipeline product approved, Bristol-Myers prepares for a landmark new drug filing, and AbbVie continues its never-ending quest to buy Shire.
Sean Williams, The Motley Fool, The Motley Fool
Sat, 07/12/2014 - 12:57pm
Anacor gets a key pipeline product approved, Bristol-Myers prepares for a landmark new drug filing, and AbbVie continues its never-ending quest to buy Shire.